A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
- Status
- RECRUITING
- Phase
- PHASE4
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
- Status
- RECRUITING
- Phase
- NA
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
- Status
- RECRUITING
- Phase
- PHASE1
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
- Status
- RECRUITING
- Phase
- PHASE2
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Status
- RECRUITING
- Phase
- PHASE3
Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
- Status
- RECRUITING
- Phase
- PHASE2
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
- Status
- RECRUITING
- Phase
- N/A
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
- Status
- RECRUITING
- Phase
- PHASE1